Novartis Ag · SIX:NOVN
Novartis — Q1 2023 Earnings Presentation
94 slides from Novartis's earnings presentation, Apr 25, 2023
Slide 1: Q1 2023 Results Investor presentation
Company overview Financial review Conclusions Appendix References Q1 2023 Results Investor presentation 1 Investor Relations │ Q1 2023 Results
Slide 2: Disclaimer
Company overview Financial review Conclusions Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “wil
Slide 3: Company overview
Company Company overview overview Financial review Conclusions Appendix References Vas Narasimhan, M.D. Chief Executive Officer Company overview 3 NOVARTIS Q1 RESULTS | APRIL 25, 2023 | NOVARTIS INVESTOR PRESENTATION 3 Investor Relations │ Q1 2023 Results
Slide 4: Q1 summary: strong sales growth, margin expansion; raising FY 2023 guidance
Company Company overview overview Financial review Conclusions Appendix References Q1 SUMMARY Novartis delivers strong sales growth, robust margin expansion and major innovation milestones; raising FY 2023 guidance Growth and Productivity Innovation Q1, % cc Kisqali® NATALEE Ph3 met primary endpoint
Slide 5: Key 2023 readouts for high-value medicines on track
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Key 2023 readouts for high-value medicines on track Key assets* with submission enabling readouts in 2023 Kisqali® Pluvicto® Iptacopan Ph3 NATALEE trial in PSMAfore trial in mCRPC APPOINT-PNH trial in adjuv
Slide 6: Submission enabling readouts expected to increase in 2024-2025
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Submission enabling readouts expected to increase in 2024-2025 timeframe Selected key assets* with submission enabling readouts in 2024-2025 Remibrutinib Pluvicto® Pelacarsen CSU mHSPC CVRR Primary analysis
Slide 7: Kisqali NATALEE met primary endpoint in broad eBC population
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Kisqali® NATALEE study met its primary endpoint demonstrating clinically meaningful iDFS benefit in broad eBC population Kisqali® (400mg) plus ET significantly Data to be presented at an 30-60% of people wi
Slide 8: Kisqali NATALEE unique in covering a broad population of eBC
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Kisqali® NATALEE unique in covering a broad population of eBC NATALEE covers broad population in eBC Kisqali eBC opportunity Multibillion USD1 Stage II (132k)3 Stage III (39k)3 N0 Unique to NATALEE Incident
Slide 9: Iptacopan APPOINT-PNH data showed clinically meaningful Hb increases
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Iptacopan APPOINT-PNH data showed clinically meaningful increases in Hb levels for treatment-naive adult patients with PNH APPOINT-PNH: Single-arm Ph3 trial in adult patients with PNH with hemolysis (LDH >
Slide 10: Strengthening radioligand therapy pipeline
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Strengthening radioligand therapy pipeline; advancing multiple assets in clinical development Recent business development in RLT Current RLT pipeline Discovery collaboration with Bicycle Therapeutics Select
Slide 11: Q1 growth driven by Entresto, Pluvicto, Kesimpta and Kisqali
Company Company overview overview Financial review Conclusions Appendix References GROWTH Q1 growth driven by strong performance from Entresto®, Pluvicto®, Kesimpta® and Kisqali® Q1 sales Sales Growth vs. PY Growth vs. PY USD million USD million cc 1,399 306 32% 211 209 nm 384 189 100% Strong growth
Slide 12: Entresto delivering strong double-digit growth in all geographies
Company Company overview overview Financial review Conclusions Appendix References GROWTH Entresto® delivering strong double-digit growth in all geographies Sales evolution US weekly TRx1 USD m, % cc Total prescriptions (000) Ex-US US 110 Strong Q1 momentum, outpacing market2 100 US: NBRx +30% vs PY
Slide 13: Cosentyx ex-US growth offset by US decline
Company Company overview overview Financial review Conclusions Appendix References GROWTH Cosentyx® ex-US growth offset by US decline. Global FY sales expected broadly in line with PY Sales evolution USD m, % cc Ex-US US Q1 performance US: Demand growth offset by revenue deductions (incl. PY base im
Slide 14: Cosentyx HS demonstrated durable efficacy up to 1 year
Company Company overview overview Financial review Conclusions Appendix References GROWTH Cosentyx® HS demonstrated durable efficacy, sustained up to 1 year HS unmet need Cosentyx Ph3 data** Lesions and abscesses in sensitive areas Durable efficacy sustained to 1 year of the body 80 70.6 >70% with a
Slide 15: Kesimpta continues strong launch trajectory doubling sales
Company Company overview overview Financial review Conclusions Appendix References GROWTH Kesimpta® continues strong launch trajectory doubling sales vs. PY Sales evolution US weekly NBRx1 Global sales +100% (cc)2 USD m, % cc US: Growing faster than market1,2 Ex-US US 350 TRx +89% vs. PY (market +1%
Slide 16: Kisqali gaining momentum globally
Company Company overview overview Financial review Conclusions Appendix References GROWTH Kisqali® gaining momentum globally, with increasing recognition of its differentiated profile Sales evolution US metastatic BC USD m, % cc NBRx share1 R3M, % Ex-US US Q1 sales USD 415 million, +81% cc 28% US NB
Slide 17: Leqvio adoption expanding as launch progresses
Company Company overview overview Financial review Conclusions Appendix References GROWTH Leqvio® adoption expanding as we progress the launch Addressing non-clinical barriers in US US Leqvio® launch tracking Entresto® Adoption Adoption US sales evolution Facilities1 having ordered Leqvio® HCPs2 wit
Slide 18: Pluvicto uptake reflects strong benefit/risk profile
Company Company overview overview Financial review Conclusions Appendix References GROWTH Pluvicto® uptake reflects strong benefit/risk profile and unmet need in post-taxane mCRPC Sales evolution Global sales, USD m 211 Q1 sales USD 211 million (mostly US) 179 Q2 sales expected broadly in line with
Slide 19: Millburn approved for Pluvicto US supply; Zaragoza approved for EU
Company Company overview overview Financial review Conclusions Appendix References GROWTH Millburn approved for Pluvicto® commercial supply in US; Zaragoza approved for EU Expected commercial coverage by end 2023 Manufacturing site: Ivrea Millburn Indianapolis Zaragoza FDA filing in US ü Approved ü
Slide 20: Scemblix maintains strong launch momentum
Company Company overview overview Financial review Conclusions Appendix References GROWTH Scemblix® maintains strong launch momentum Sales evolution USD m Ex-US US 76 Q1 sales USD 76 million; US NBRx share at 32%1 15 Sales driven by patients resistant/intolerant to other TKIs Global rollout ongoing
Slide 21: Financial review and 2023 guidance
Company overview Financial review Financial review Conclusions Appendix References Harry Kirsch Chief Financial Officer Financial review and 2023 guidance 21 NOVARTIS Q1 RESULTS | APRIL 25, 2023 | NOVARTIS INVESTOR PRESENTATION 21 Investor Relations │ Q1 2023 Results
Slide 22: Strong top and bottom line growth in Q1
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Strong top and bottom line growth in Q1 Group1 Q1 Change vs. PY USD million 2023 % USD % cc Net Sales 12,953 3 8 Core Operating income 4,413 8 15 Operating income 2,856 0 9 Net income 2,294 3 14 Core
Slide 23: Continuing core margin improvements for Group driven by IM
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Continuing core margin improvements for Group driven by IM Q1 2023 Net sales Core operating income Core margin change vs. PY1 change vs. PY1 Core margin 1 change vs. PY1 % cc % cc % %pts cc Innovativ
Slide 24: Raising 2023 guidance for Novartis excluding and including Sandoz
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Raising 2023 guidance for Novartis excluding and including Sandoz Expected, barring unforeseen events; growth vs. PY in cc Previous guidance Innovative Medicines Sales expected to grow mid single dig
Slide 25: Raising Sandoz 2023 top line guidance
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Raising Sandoz 2023 top line guidance Expected, barring unforeseen events; growth vs. PY in cc Previous guidance Sales expected to grow mid single digit (Low-to-mid) 2023 Core OpInc expected to decli
Slide 26: Sandoz well positioned; planned spin-off on track for H2
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Sandoz well positioned in a growing market; planned spin-off on track for H2 Q1 performance1 Continuing to deliver On track for planned on biosimilar promise Sandoz spin-off2 in H2 2023 Sales USD 2.4
Slide 27: Group Core OpInc to grow high single digit
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Group Core OpInc to grow high single digit driven by business momentum and Pluvicto® manufacturing capacity expansion 2023 key drivers of core operating income (Group) Vs. PY (cc) Illustrative + In-m
Slide 28: Expected currency impact for full year 2023
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Expected currency impact for full year 2023 Currency impact vs. PY %pts, assuming late-April exchange rates prevail in 2023 FX impact on Net sales FX impact on Core operating income 0 -1 -3 to -4 -6
Slide 29: Vas Narasimhan, Chief Executive Officer
Company overview Financial review Conclusions Conclusions Appendix References Vas Narasimhan, M.D. Chief Executive Officer 29 NOVARTIS Q1 RESULTS | APRIL 25, 2023 | NOVARTIS INVESTOR PRESENTATION 29 Investor Relations │ Q1 2023 Results
Slide 30: Conclusions
Company overview Financial review Conclusions Conclusions Appendix References Conclusions Strong start to 2023: Growth particularly driven by Entresto®, Kisqali® and Kesimpta® Launches: Pluvicto® and Scemblix® continue strong trajectory, Leqvio® progresses steadily Confidence in near- to mid-term gr
Slide 31: Appendix
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix 31 Investor Relations │ Q1 2023 Results
Slide 32: 2023 expected key events
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION 2023 expected key events H1 2023 H2 2023 Status update – as of end Q1 Regulatory Cosentyx®
Slide 33: Our pipeline projects at a glance
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Our pipeline projects at a glance Phase 1/2 Phase 3 Registration Total Innovative medicine
Slide 34: Continuing refinement of R&D portfolio
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Continuing refinement of R&D portfolio to prioritize high-value transformative medicines ~
Slide 35: Novartis pipeline in Phase 1
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 1 20 lead indications Lead indication Solid tumors Hematology C
Slide 36: Novartis pipeline in Phase 2
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 2 23 lead indications Lead indication Solid Tumors Hematology C
Slide 37: Novartis pipeline in Phase 3
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 3 8 lead indications Lead indication Solid Tumors Hematology Co
Slide 38: Novartis pipeline in registration
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in registration 1 lead indication Lead indication Solid Tumors Cardiovas
Slide 39: Novartis submission schedule: new molecular entities
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis submission schedule New Molecular Entities: Lead and supplementary indications Ca
Slide 40: Novartis submission schedule: existing brands
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis submission schedule Supplementary indications for existing brands Cardiovascular
Slide 41: Zolgensma sales declined mainly due to pricing dynamics
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations GROWTH Zolgensma® sales declined mainly due to pricing dynamics Maintaining leading share in US in <2 years1;
Slide 42: FY 2023 guidance on other financial KPIs
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations FINANCIAL PROFILE FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Group | Full ye
Slide 43: Net debt increased by USD 7.9bn
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations FINANCIAL PROFILE Net debt increased by USD 7.9bn mainly due to dividends and share buybacks, partially offse
Slide 44: Clinical Trials Update
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Clinical Trials Update Includes selected ongoing
Slide 45: Cardiovascular
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cardiovascular 45 Investor Relations │ Q1 2023 Re
Slide 46: iptacopan - CFB inhibitor (APPLAUSE-IgAN)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor NCT04578834 APPLAUSE-Ig
Slide 47: iptacopan - CFB inhibitor (C3G)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inhibit
Slide 48: Leqvio - ORION-4 and ORION-8
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - s
Slide 49: Leqvio - ORION-16 and ORION-13
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - s
Slide 50: Leqvio - VICTORION-2P and 1P
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - s
Slide 51: pelacarsen - ASO targeting Lp(a)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other pelacarsen - Antisense oligonucleotide (ASO) targ
Slide 52: XXB750 - NPR1 agonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other XXB750 - NPR1 agonist NCT05562934 (CXXB750B12201)
Slide 53: Immunology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Immunology 53 Investor Relations │ Q1 2023 Result
Slide 54: Cosentyx - Lupus Nephritis and Giant cell arteritis
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A i
Slide 55: Cosentyx - Rotator cuff tendinopathy
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A i
Slide 56: Cosentyx - Polymyalgia rheumatica
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor NCT05767034 REPLENIS
Slide 57: ianalumab - AMBER and SIRIUS-LN
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 58: ianalumab - Sjögren's syndrome
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 59: ianalumab - SIRIUS-SLE 1 and 2
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 60: ligelizumab - IgE Inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ligelizumab - IgE Inhibitor NCT04984876 (CQGE031G
Slide 61: LNA043 - ANGPTL3 agonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other LNA043 - ANGPTL3 agonist NCT04864392 ONWARDS (CLN
Slide 62: remibrutinib - REMIX-1 and REMIX-2
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - BTK i
Slide 63: Neuroscience
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Neuroscience 63 Investor Relations │ Q1 2023 Resu
Slide 64: Mayzent - S1P receptor modulator
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Mayzent® - S1P1,5 receptor modulator NCT04926818
Slide 65: MIJ821 - NR2B negative allosteric modulator
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other MIJ821 - NR2B negative allosteric modulator (NAM)
Slide 66: remibrutinib - REMODEL-1 and REMODEL-2
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - BTK i
Slide 67: Zolgensma - STEER and STRENGTH
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Zolgensma® - SMN1 gene replacement therapy Zolgen
Slide 68: Oncology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Oncology 68 Investor Relations │ Q1 2023 Results
Slide 69: ianalumab - VAYHIT1 and VAYHIT2
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 70: ianalumab - VAYHIA
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor NCT05648968 VAYHIA (
Slide 71: iptacopan - APPELHUS
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor NCT04889430 APPELHUS (C
Slide 72: Jakavi - REACH4 and REACH5
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Jakavi® - JAK1/2 inhibitor Jakavi® - JAK1/2 inhib
Slide 73: JDQ443 - KRAS inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other JDQ443 - KRAS inhibitor NCT05132075 KontRASt-02 (
Slide 74: Kisqali - NATALEE
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Kisqali® - CDK4 inhibitor NCT03701334 NATALEE (CL
Slide 75: niseovkitug - TGF-beta 1 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other niseovkitug - TGF-beta 1 inhibitor NCT04935359 da
Slide 76: Piqray - PI3K-alpha inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Piqray® - PI3K-alpha inhibitor NCT04729387 EPIK-O
Slide 77: Pluvicto - PSMAfore and PSMAddition
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Pluvicto® - Radioligand therapy target PSMA Pluvi
Slide 78: Rydapt - Multi-targeted kinase inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Rydapt® - Multi-targeted kinase inhibitor NCT0359
Slide 79: sabatolimab - TIM3 antagonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other sabatolimab - TIM3 antagonist sabatolimab - TIM3
Slide 80: Scemblix - ASC4FIRST
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Scemblix® - BCR-ABL inhibitor NCT04971226 ASC4FIR
Slide 81: TNO155 - SHP2 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other TNO155 - SHP2 inhibitor NCT03114319 (CTNO155X2101
Slide 82: Other
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars Other 82
Slide 83: Ophthalmology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Biosimi
Slide 84: Beovu - VEGF Inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Biosimi
Slide 85: libvatrep - TRPV1 antagonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Biosimi
Slide 86: Global Health
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 87: Adakveo - P-selectin inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 88: cipargamin - PfATP4 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 89: Coartem - artemisinin combination therapy
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 90: ganaplacide - non-artemisinin inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimi
Slide 91: Biosimilars
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars Biosimila
Slide 92: aflibercept - VEGF inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars afliberce
Slide 93: Abbreviations
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Abbreviations Abbreviations AI Auto-injector IgAN IgA nephropathy AIH Autoimmune hepatitis IPF Idiopathic pulmonary fibrosis aHUS a
Slide 94: References
Company overview Financial review Conclusions Appendix References References References Cosentyx® 1 Matusiak Ł. Br J Dermatol. 2020;183(6):e171-e177. 2 G6 market estimations based on IQVIA PADDS 2021. 3 Kimball A, et al. N Engl J Med. 2016;375:422–434. 4 Data on file. IQVIA PADSS. Novartis Pharmaceu